RECRUITING · INTERVENTIONAL · TREATMENT study · Advanced Malignant Solid Neoplasm · Phase 1 · Enrollment 35 · Sponsor: National Cancer Institute (NCI)
Official title: Pilot Study of CBX-12 Pharmacodynamics in Patients With Advanced Solid Tumors
Summary: This phase I trial studies how well CBX-12 works in treating patients with solid tumors that have spread from where they first started (primary site) to started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or other places in the body (metastatic). CBX-12 works by binding to a protein called TOP1 that is present inside the cells. This allows CBX-12 to kill the cancer cells by damaging their DNA, resulting in cancer cell death. This trial is being done to find out if this approach is better or worse than the usual approach for advanced cancers.
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Study type: INTERVENTIONAL
Primary purpose: TREATMENT
Phases: PHASE1
Enrollment: 35 (ESTIMATED)
Status: RECRUITING
Completion: 2026-10-15 (ESTIMATED)